Background Cross-sectional studies on human hypertension have suggested an association between sodium intake and left ventricular hypertrophy (LVH).
Effects on Left Ventricular Hypertrophy of Long-term Nonpharmacological Treatment With
Sodium Restriction in Mild-to-Moderate Essential Hypertension Antti M. Jula, MD; Hannu M. Karanko, MD Background Cross-sectional studies on human hypertension have suggested an association between sodium intake and left ventricular hypertrophy (LVH).
Methods and Results The effects on LVH of a nonpharmacological treatment program based mainly on sodium restriction were examined by serial echocardiography in a 12-month controlled, randomized study that included 76 previously untreated subjects with uncomplicated mild-to-moderate hypertension. The mean daily sodium excretion of 38 subjects randomized into the treatment group decreased from 195±95 to 94±73 mmol (P<.001) at 6 months and to 109±74 mmol (P<.001) at 12 months. This was accompanied by a weight decrease from 81.4±18.0 to 79.2±17.4 kg (P<.001) at 6 months and to 80.6± 17.5 kg (NS) at 12 months. The net blood pressure decrease (difference in change from baseline between the treatment and control groups) was 8.9 mm Hg (P<.001) in systolic blood pressure and 6.5 mm Hg (P<.001) in diastolic blood pressure during the first 6 months and 6.7 mm Hg H ypertensive subjects with left ventricular hypertrophy are at increased risk of cardiovascular mortality."2 The degree of echocardiographic left ventricular hypertrophy is usually associated with blood pressure level3-6 and the degree of obesity3'4,67 as well as with increased blood pressure reactivity8'9 and, according to some studies, weakly with aging.34 Re- cently, increased dietary sodium intake has been found to be an indicator of left ventricular hypertrophy.7"10 It has also been suggested that neurohumoral as well as intracellular factors may modify the hypertrophic response of elevated blood pressure." Regression of left ventricular hypertrophy has been shown to occur in subjects treated for essential hypertension with certain antihypertensive drugs""12 and with weight reduction.13 However, no data are available on the possible effects of long-term sodium restriction on left ventricular hypertrophy.
Our recent study showed that a long-term nonpharmacological treatment mainly based on sodium restriction effectively reduces blood pressure in most patients suffering from mild-to-moderate essential hyperten-sion.14 With data collected in that trial, our aim in the present study was to investigate the effects of long-term nonpharmacological treatment with sodium restriction on left ventricular dimensions and hemodynamics using serial echocardiography. In addition, we wanted to identify factors associated with increased left ventricular mass at baseline.
Methods Subjects
Ninety-one subjects (60 men and 31 women; age, 31 to 55 years) with essential !typertension (World Health Organization stage I or II) were randomly allocated into a nonpharmacological treatment group or a control group. The diagnosis of uncomplicated essential hypertension was based on clinical examination including history, physical examination, exercise ECG, and pertinent biochemical tests. Patients with hemodynamically significant valvular disease were not included. The patients had been previously untreated or had been without antihypertensive medication for at least 1 year. The subjects were not taking oral contraceptives or any other drug on a regular basis. Three subjects dropped out of the treatment group and two out of the control group during the 1-year follow-up. For anatomic reasons, echocardiography could not be successfully done in 10 patients. Thus, the final study population consisted of 76 hypertensive subjects at baseline and at 6-and 12-month follow-up.
Patients randomized into the treatment group also received general advice on losing weight if necessary and reducing the intake of saturated fats. The control subjects did not receive instructions on nonpharmacological treatment of hypertension. Antihypertensive medication was not used in either group.
The following measurements were done in treatment and control subjects throughout the study. Diet was monitored through 7-day dietary records; 24-hour urine samples were taken to determine sodium, potassium, and creatinine levels; and weight was measured. All these measurements were done at baseline and at 3-, 6-, 9-, and 12-month follow-up. Seated blood pressure was measured in duplicate with a Hawksley random-zero sphygmomanometer using first and fifth Korotkoff sounds. The measurements were always done by the same trained technician. Three measurements were done at 1-week intervals during the run-in period, and the mean value of the last two measurements was used as baseline blood pressure. Blood pressure was measured monthly during the follow-up.
Blood samples for measurements of blood glucose and plasma insulin were taken at baseline after 12 hours of fasting. Blood glucose was measured with the glucose dehydrogenase method. Plasma insulin was determined by a commercial method (antisera M8170 and M8309, Novo). Echocardiography Treatment and control subjects underwent two-dimensionally controlled M-mode echocardiography at baseline as well as at 6-and 12-month follow-up using an ATL MARK III ultrasonoscope and a real-time scanhead (720A) with a 3-MHz transducer. Echocardiograms with simultaneous one-channel ECGs were obtained with the patient in the partial left decubitus position and recorded on light-sensitive paper at a paper speed of 50 mm/s. All echocardiographic studies were done blindly to the treatment allocation of individual patients by the same experienced investigator (H.M. Karanko), who also analyzed the tracings blindly, in random order, after the study period. Measurements were made according to the recommendations of the American Society of Echocardiography (ASE), digitized, and processed by using a Hewlett Packard 9845B minicomputer and a Hewlett Packard 9874A digitizing table. Leading edge-to-leading edge convention was used.15 Left ventricular echograms were measured at or immediately below the tips of mitral leaflets and averaged from at least five heart cycles.
Left ventricular mass was calculated from end-diastolic wall thicknesses and cavity dimensions using the formula described by Troy and coworkers. 16 Corrected left ventricular mass was calculated using the equation developed by Devereux and coworkers'7: 0.80 (ASE-cube left ventricular mass)+0.6. Enddiastolic relative wall thickness (end-diastolic posterior wall thickness divided by half of the end-diastolic left ventricular internal dimension) was calculated as an index of concentric left ventricular hypertrophy. 18Left ventricular systolic function was described by fractional shortening as the difference of diastolic and systolic left ventricular internal dimensions divided by diastolic left ventricular internal dimension. Left ventricular volumes were estimated by the cube function formula and used to calculate stroke volume as a difference of end-diastolic and end-systolic left ventricular volumes. Cardiac output was calculated as stroke volume multiplied by heart rate. Total peripheral resistance was calculated as the ratio of mean arterial pressure (diastolic blood pressure plus one third of the difference of systolic and diastolic blood pressures) to cardiac output and expressed as dyne * s * cm-5. End-systolic wall stress was determined using a previously described formula19 derived from an angiographically validated method. 20 Blood pressure for the calculations of total peripheral resistance and end-systolic wall stress, measured by the same trained nurse throughout the study, was the average of two measurements performed with the patient in the supine position and measured with a mercury sphygmomanometer during echocardiography.
Statistical Analysis
Statistical analysis of the data was performed with SAS computer programs (SAS Institute). Unpaired t test was used to test the significance of the difference between the study groups at baseline. ANOVA for repeated measures at different time points was used to test the significance of changes within and between the study groups. Bonferroni's rule was used to correct significance levels of changes from a to a/2.
The following analyses were performed from baseline data after combining subjects in the treatment and control groups. Pearson's correlation coefficients were calculated to indicate correlations between left ventricular mass/height and other variables as well as correlations between body mass index and fasting plasma insulin levels. Multivariate regression analysis was used to describe factors associated with left ventricular mass/height and 24-hour urine sodium excretion.
Pearson's correlation coefficients were calculated to relate changes in left ventricular mass to changes in blood pressure, body weight, 24-hour urine sodium, and the proportion of fats in total energy intake among subjects in the treatment group. The changes in left ventricular mass of all 76 hypertensive subjects were examined in stepwise multivariate regression analyses with baseline left ventricular mass index (LVMI), with dietary intervention (1, intervention; 0, no intervention), and with the individual changes in weight and diastolic, systolic, and mean arterial blood pressures (baseline blood pressure subtracted from the mean of the six monthly blood pressure values at 1 to 6 months and 7 to 12 months) as independent variables. Left ventricular mass indexed by body surface area was used during follow-up as an index of left ventricular hypertrophy to adjust changes in left ventricular mass for changes in weight.
Results
No significant differences were seen in baseline clinical and echocardiographic ventricular and hemodynamic characteristics between the treatment and control groups (Tables 1 to 3 ).
The net blood pressure decrease (difference in change from baseline between the treatment and control groups) was 8.9 mm Hg in systolic blood pressure and 6.5 mm Hg in diastolic blood pressure during the first 6 months and 6.7 mm Hg in systolic blood pressure and 3.8 mm Hg in diastolic blood pressure during the last 6 months (see Table 1 ). Twenty-four-hour urinary sodium excretion markedly decreased in the treatment group, but it also tended to decrease toward the end of the study in some control subjects (Table 1) . A small, temporary weight decrease was seen in the treatment group. The proportion of fats from total energy intake decreased in the treatment group from 41% to 36%, mainly as a result of reduction in saturated fatty acid intake. The intake of polyunsaturated fatty acids, dietary fiber, alcohol, calcium, and magnesium remained unchanged in the treatment group. Nutrient intake was unchanged in control subjects. Factors Associated With Left Ventricular Mass/Height at Baseline Factors associated with left ventricular mass/height were examined by univariate and multivariate regression analyses combining treatment and control subjects at baseline. Left ventricular mass/height correlated positively and significantly with age (r-.28, P<.OS), weight 4 .7% during follow-up in the treatment group, whereas no changes were seen in these parameters in the control group. Peripheral resistance, peripheral resistance index, cardiac output, cardiac index, fractional shortening, and end-systolic wall stress did not change significantly in the two groups. The effects of the treatment on characteristics of left ventricular hypertrophy and hemodynamic variables did not differ between the two sexes.
Subjects in the treatment group were divided into two groups of equal size according to the median values of the baseline LVMI of men (133 g/m2) and women (107 g/m2). There were no significant differences between these two groups at baseline in age, weight, body mass index, and systolic blood pressure (Table 3) . However, diastolic blood pressure was higher (P<.01) in subjects with LVMI of more than the median compared with subjects with LVMI equal to or less than the median.
In subjects with LVMI of more than the median, the treatment reduced left ventricular mass by 8.6% and left ventricular mass indexed by body surface area by 7.1%, whereas both parameters remained unchanged in those with LVMI equal to or less than the median (Table 4) . In control subjects with LVMI of more than the median (n= 15), left ventricular mass was 256 +43 g at baseline, 257±56 g at 6 months, and 250±53 g at 12 months (P=NS compared with baseline). A temporary decrease in fractional shortening was observed in the subjects of the treatment group with LVMI of more than the median (Table 5) . End-systolic wall stress decreased and total peripheral resistance tended to decrease in subjects with LVMI equal to or less than the median, but the changes were nonsignificant compared with changes in those with LVMI of more than the median.
Relations of Dietary and Blood Pressure Changes to Changes in Left Ventricular Mass
In the treatment group, the changes in left ventricular mass did not correlate with changes in blood pressure, body weight, 24-hour urine sodium, and the proportion of fats from total energy intake. (Table 6 ). The alternative models including either dietary intervention or changes in mean arterial pressure produced almost the same R2 value, particularly at 12 months. The explanatory power of dietary intervention and of the change in mean arterial pressure with respect to change in left ventricular mass decreased when both variables were included in the same model (Table 6 ).
Discussion
Several factors may cause left ventricular hypertrophy in essential hypertension. Increased pressure overload leads in the long term to concentric hypertrophy of the left ventricle." On the other hand, increased venous tone, as observed in sodium-sensitive21 and low-renin22 hypertensive subjects, results in redistribution of the circulating blood volume to the cardiopulmonary area. An increased volume overload in turn may lead to eccentric hypertrophy with initial dilatation of the left ventricle and a subsequent increase in muscle mass. 23 However, some of the left ventricular hypertrophy may be explained by the trophic actions of catecholamines and angiotensin II on heart muscle and connective tissue" and by local factors stimulating the protein synthesis of the myocardium. 24, 25 We found that higher diastolic blood pressure, probably an indicator of pressure overload, explained increased left ventricular mass markedly and independent of sex, body mass index, or 24-hour urine sodium excretion.
Obesity and male sex were statistically powerful independent indicators of increased left ventricular mass. However, their influence on left ventricular mass may partly be mediated by sodium balance. In our study, the mean 24-hour urinary sodium excretion at baseline was about 80% higher in men than in women. A higher body mass index was associated with higher sodium No significant differences were seen in any baseline variable between subjects in the upper and lower halves of the LVMI distribution.
intake, confirming earlier reports. 26 In agreement with many previous reports,2728 in our subjects obesity was related with hyperinsulinemia, which in turn may lead to increased sodium retention29 through increased renal tubular sodium reabsorption.30 '3' In our study, sodium restriction was accompanied by a slight temporary weight decrease comparable to that of earlier studies on sodium restriction.3233 According to previous studies,33 volume depletion can be estimated to account for most of it. In some studies,34 weight reduction has been shown to reduce blood pressure only when combined with sodium restriction, although opposite views have been expressed in studies using hypocaloric, ketogenic, and highly natriuretic diets. 35 The effects of considerable changes in dietary fat on blood pressure are controversial.3637 In our study, changes in weight and fat intake did not explain changes in blood pressure14 and left ventricular mass. The decrease in left ventricular mass was probably by chance somewhat larger in the group of treated subjects with a small or no decrease in energy intake from fats. Thus, the net changes (differences in changes between treatment and control groups) in blood pressure as well as in left ventricular characteristics have to be interpreted mainly as a result of sodium restriction. Intraindividual variation in daily sodium intake,3839 interindividual differences in both baseline and achieved sodium intake, and interindividual differences in sodium sensitivity may explain why no correlations occurred between changes in 24-hour urine sodium and changes in left ventricular mass.
The changes in mean arterial pressure were significantly associated with the changes in left ventricular mass in the multivariate models for all 76 hypertensive subjects. In the multivariate models, the changes in mean arterial pressure could be easily substituted for subjects with mild-to-moderate hypertension. Longterm nonpharmacological treatment with moderate sodium restriction initially decreased left ventricular hypertrophy as a result of decreased blood pressure.
